News

Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics ...

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...
STAT3d

Pharmalittle: We’re reading about a new Novo Nordisk CEO, an FDA reversal on Sarepta, and more

Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...

Brown University borrows $500 million more amid ‘deep financial challenges’

Brown University took out another private loan, securing a $500 million agreement after the Ivy League school warned of “deep ...
Business Wire4d

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

Sarepta Owes $100 Million to Partner as Financial Pressure Grows

Arrowhead Pharmaceuticals Inc. said Monday that it’s owed a $100 million milestone payment from Sarepta Therapeutics Inc. within the next two months, pressuring the beleaguered biotech company just ...

Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals ( NASDAQ: ARWR) Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics ( NASDAQ: SRPT ).

Sarepta Therapeutics: Beaten Down, But Not Out

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.